At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial With Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis
In Brief
A Phase 2 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 52 participants across 1 site.
Detailed Summary
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis.
Study Details
Timeline
Interventions
Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.